摘要
非核苷类逆转录酶抑制剂（non—nucleoside reversetran—scriptaseinhibitros，NNRTIs）正越来越频繁地被用作抗艾滋病三联疗法组分之一，但不良反应和易发生耐药是NNRTIs的主要缺陷。利匹韦林（rilpivirine，RPV，商品名Edurant）是由美国Tibotec公司开发的新型NNRTIs，于2011年5月20日获美国FDA批准上市，具有易合成、抗病毒活性强、口服生物利用度高、安全性好等特点。
出处
《中国药学杂志》
CAS
CSCD
北大核心
2013年第24期2169-2171,共3页
Chinese Pharmaceutical Journal
参考文献16
-
1DAS K, BAUMAN J, CLARK A. et al. High-resolution struc- tures of HIV-1 reverse transcriptase/TMC278 complexes: Strate- gic flexibility explains potency against resistance mutations [ J ]. Proc Natl Acad Sci, 2008, 105: 1466-1471.
-
2CRAUWELS H, VINGERHOETS J, RYAN R, et al. Pharmaco- netic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects [ J ]. Antivir Ther, 2012,17 (3):439-446.
-
3DE BETHUNE M, ANDRIES K, AZIJN H, et al. TMC-278, a new potent NNRTI, with an increased barrier to resistance and good pharmacokinetic profile [ R]. 12th Conference on Retrovir- uses and Opportunistic Infections ; 22-25 February 2005, Boston, MA.
-
4DICKINSON L, KHOO S, BACK D. Pharmacokineties and drug- drug interactions of antiretrovirals: An update [ J]. Antiviral Res, 2010,85 ( 1 ) : 176-189.
-
5JAYAWEERA D, DILANCHIAN P. RILPIVIRINE. First-line treatment of HIV infection : Efavirenz is better documented [ J]. Prescrire lnt, 2012, 21 (132) :262-265.
-
6COHEN C J, ANDRADE-VILLANUEVA J, CLOTET B, et al. Rilpivirine versus efavirenz with two background nucleoside or nude- otide reverse transcriptase inhibitors in treatment-naive adults infec- ted with HIV-1 (THRIVE) : A phase 3, randonfised, non-inferiority trial [J]. Lancet, 2011, 378(9787) :229-237.
-
7COHEN C J, MOLINA J M, CASSETYI I, et al. Week 96 effica- cy and safety of rilpivirine in treatment-nai've, HIV-1 patients in two phase III randomised trials [ J]. AIDS, 2012, 14 (3) :168- 178.
-
8SHARMA M, SARAVOLATZ L D. Rilpivirine: A new non-nu- cleoside reverse transcriptase inhibitor [ J ]. J Antimicrob Che- moth, 2012, 55(2) :107-113.
-
9NIMISH PATEL, CHRISTOPHER D MILLER. New option for management of HIV-1 infection in treatment-naive patients : Once- daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir [J]. HIVAIDS (Auekl), 2012, 4: 61-71.
-
10CALVIN J. COHEN, JEAN-MICHEL MOLINA, PEDRO CAHN, et al. Efficacy and safety of rilpivifine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials [J]. Clin Sei, 2012, 60(1) :33-42.
-
1三种国产抗艾滋病新药面市[J].山东卫生,2004(2):23-23.
-
2美国FDA批准雅培儿童抗艾滋病新药[J].中国医药导报,2007,4(12Z):2-2.
-
3抗艾滋病新药[J].化工文摘,2001(2):43-43.
-
4上海科学家合成5种抗艾滋病新药[J].国际医药卫生导报,2001,7(11B):22-22.
-
5葛兰素史克在我国推出抗艾滋病新药[J].国外科技动态,2002(12):38-38.
-
6张翼（编译）.美国FDA批准艾滋病治疗新药利匹韦林[J].药品评价,2011,8(14):22-22.
-
7李晓静,赵临襄.利匹韦林[J].中国药物化学杂志,2011,21(5):411-411.
-
8康银花,范鸣.逆转录酶抑制剂——Rilpivirine[J].药学进展,2008,32(6):282-284. 被引量：1
-
9马培奇.抗艾滋病新药依曲韦林及其临床地位与市场预测[J].中国制药信息,2010,26(7):16-18.
-
10抗艾滋病一类新药进入临床试验[J].中国医药技术经济与管理,2008,2(5):8-8.
